ダクラタスビル/アスナプレビル投与による肝機能障害発現の危険因子に関する後方視的調査

抄録

Treatment for chronic hepatitis C virus (HCV) infection has been developed worldwide with all-oral treatment gaining the attention of not only medical staff, but also patients recently. The therapy with daclatasvir and asunaprevir is a first interferon-free regimen for patients with HCV approved in Japan. This therapy demonstrates marked antiviral effects in patients without NS5A and NS3 resistance-associated variants. However, adverse events leading to the discontinuation of treatment are reported. Therefore, we researched the characteristics of patients retrospectively in order to predict the development of adverse event symptoms.

A retrospective analysis was performed on 39 patients who were prescribed daclatasvir and asunaprevir in the University of Miyazaki Hospital between September 2014 and August 2015. We focused on liver injury as adverse events.

Liver injury was assessed with ALT increase. The physical constitution of patients was not related to the development of liver injury. To analyze patient background at the onset of treatment, the serum albumin level of patients with ALT increase was significantly lower than that of patients without ALT increase. These results suggest that the serum albumin level at the onset of treatment is a predictive factor of liver injury in the therapy with daclatasvir and asunaprevir.